We are live on ! Find out more
PACB icon

Pacific Biosciences
PACB

141 hedge funds and large institutions have $432M invested in Pacific Biosciences in 2016 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 70 increasing their positions, 27 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 27

93% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 15

9% more funds holding

Funds holding: 129 → 141 (+12)

11% less capital invested

Capital invested by funds: $487M → $432M (-$54.8M)

28% less call options, than puts

Call options by funds: $4.08M | Put options by funds: $5.66M

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
141
Holders Change
+12
Holders Change %
+9.3%
% of All Funds
3.76%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
29
Increased
70
Reduced
27
Closed
15
Calls
$4.08M
Puts
$5.66M
Net Calls
-$1.58M
Net Calls Change
-$876K

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$22.9M
2
RCM
Raging Capital Management
New Jersey
+$15.9M
3
BM
Bridger Management
New York
+$9.91M
4
Capital World Investors
Capital World Investors
California
+$8.15M
5
Wells Fargo
Wells Fargo
California
+$8.04M

Top Sellers

1
CCM
Consonance Capital Management
New York
-$31.1M
2
EAM
EverPoint Asset Management
Connecticut
-$8.07M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$7.65M
4
Renaissance Technologies
Renaissance Technologies
New York
-$7.17M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$6M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
126
Tower Research Capital (TRC)
New York
$64K +$80.3K +8,792 +2,363%
Walleye Trading
127
Walleye Trading
New York
$51K +$54.3K +5,947 +447%
WA
128
WFG Advisors
Texas
$39K -$10.8K -1,186 -18%
ST
129
Smithfield Trust
Pennsylvania
$38K – – –
BNP Paribas Financial Markets
130
BNP Paribas Financial Markets
France
$20.8K +$27K +2,961 New
Zurich Cantonal Bank
131
Zurich Cantonal Bank
Switzerland
$16K – – –
US Bancorp
132
US Bancorp
Minnesota
$14K – – –
Royal Bank of Canada
133
Royal Bank of Canada
Ontario, Canada
$9K – – –
Barclays
134
Barclays
United Kingdom
$7K -$752K -82,329 -99%
LTFS
135
Ladenburg Thalmann Financial Services
Florida
$5K +$3.65K +400 +133%
Federated Hermes
136
Federated Hermes
Pennsylvania
$4K -$301 -33 -5%
PNC Financial Services Group
137
PNC Financial Services Group
Pennsylvania
$3K -$128 -14 -4%
MA
138
MUFG Americas
New York
$2K – – –
CA
139
Commerzbank Aktiengesellschaft
Germany
$1.47K +$1.45M +159,100 +324%
QI
140
QS Investors
New York
$1K +$329 +36 New
MAM
141
Meeder Asset Management
Ohio
$1K +$1.61K +176 New
EAM
142
EverPoint Asset Management
Connecticut
– -$8.07M -950,000 Closed
Adage Capital Partners
143
Adage Capital Partners
Massachusetts
– -$7.65M -900,000 Closed
Point72 Asset Management
144
Point72 Asset Management
Connecticut
– -$6M -706,500 Closed
GTC
145
Ghost Tree Capital
New York
– -$5.95M -700,000 Closed
BIM
146
Bogle Investment Management
Massachusetts
– -$4.98M -585,609 Closed
Two Sigma Investments
147
Two Sigma Investments
New York
– -$946K -111,292 Closed
EI
148
EAM Investors
California
– -$936K -110,172 Closed
EMG
149
Ellington Management Group
Connecticut
– -$264K -31,100 Closed
QSS
150
Quantitative Systematic Strategies
Florida
– -$150K -17,242 Closed
3 4 5
6
7

PACB Hedge Fund Activity: Q2 2016 in Review

141 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q2 2016, worth a combined $432M — down 11% from $487M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PACB positions and 15 closed out — a net gain of 14 holders — while 70 added to existing stakes and 27 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $22.9M. The largest seller was Consonance Capital Management, cutting an estimated $31.1M.

  • 141 institutional investors held Pacific Biosciences (PACB) as of Q2 2016, up from 129 in Q1 2016.
  • Funds reported $432M of Pacific Biosciences stock for Q2 2016, down 11% quarter-over-quarter.
  • 29 funds opened new Pacific Biosciences positions in Q2 2016 and 15 closed out, a net change of +14 holders.
  • The largest Pacific Biosciences buyer in Q2 2016 was Lord, Abbett & Co, an estimated $22.9M added.
  • The largest Pacific Biosciences seller in Q2 2016 was Consonance Capital Management, an estimated $31.1M sold.

Based on aggregated 13F filings for Q2 2016.